A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset

British Journal of Dermatology

Volumn 158, Issue 5, 2008, Pages 1063-1068

  Derk, C T ^a   Huaman, G ^a   Jimenez, S A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

D penicillamine; Scleroderma; Systemic sclerosis; Tissue fibrosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTINUCLEAR ANTIBODY; CALCIUM CHANNEL BLOCKING AGENT; CENTROMERE ANTIBODY; PENICILLAMINE; PREDNISONE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PEMPHIGUS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZATION; RASH; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS;

ANTIRHEUMATIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PENICILLAMINE; RETROSPECTIVE STUDIES; SCLERODERMA, DIFFUSE; SKIN;

EID: 42049114498     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08452.x     Document Type: Article

References (35)

1. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004 140 : 37 50.
2. Thurm RH, Alexander JC. Captopril in the treatment of scleroderma renal crisis. Arch Intern Med 1984 144 : 733 5.
3. Zawada ET Jr., Clements PJ, Furst DA et al. Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron 1981 27 : 74 8.
4. White B, Moore WC, Wigley FM et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000 132 : 947 54.
5. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002 346 : 896 903.
6. Steen VD, Medsger TA Jr., Rodnan GP. D-penicillamine therapy in progressive systemic sclerosis (scleroderma). Ann Intern Med 1982 97 : 652 8.
7. Jimenez SA, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991 18 : 1496 503.
8. Clements PJ, Furst DE, Wong WK et al. High-dose (HI-DPA) vs low-dose (LO-DPA) penicillamine in early diffuse systemic sclerosis (SSc) trial: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999 42 : 1194 203.
9. Black CM, Silman AJ, Herrick AI et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999 42 : 299 305.
10. Grasseger A, Schuler G, Hessenberger G et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 1998 139 : 639 48.
11. Seibold JR, Korn JH, Simms R et al. Recombinant human relaxin in the treatment of scleroderma: a randomized double-blind placebo-controlled trial. Ann Intern Med 2000 132 : 871 9.
12. Pope JE, Bellamy N, Seibold JR et al. A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001 44 : 1351 8.
13. White B, Bauer EA, Goldsmith LA et al. Guidelines for clinical trials in systemic sclerosis (scleroderma): I. Disease-modifying interventions. Arthritis Rheum 1995 38 : 351 60.
14. Harris ED Jr., Sjoerdsma A. Effect of penicillamine on human collagen and its possible application to treatment of scleroderma. Lancet 1966 ii : 996 9.
15. Lewins EG, Cripps AW, Clancy RL, Major GA. Penicillamine-induced immunosuppression: in vitro studies of inhibition of immunoglobulin synthesis. J Rheumatol 1982 9 : 677 84.
16. Lipsky PE. Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphocyte proliferation by copper- or ceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes. J Clin Invest 1984 73 : 53 65.
17. Freundlich B, Jimenez SA. Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy. Clin Exp Immunol 1987 69 : 375 84.
18. Nimni ME, Bavetta LA. Collagen defect induced by penicillamine. Science 1965 150 : 905 7.
19. Nimni ME. A defect in the intramolecular and intermolecular cross-linking of collagen caused by penicillamine. I. Metabolic and functional abnormalities in soft tissues. J Biol Chem 1968 243 : 1457 66.
20. Nimni ME, Deshmukh K, Gerth N. Collagen defect induced by penicillamine. Nat New Biol 1972 240 : 220 1.
21. 3H-collagen in vivo. Biochem Biophys Acta 1969 194 : 504 10.
22. Bluestone R, Grahame R, Holloway V et al. Treatment of systemic sclerosis with D-penicillamine. A new method of observing the effects of treatment. Ann Rheum Dis 1970 29 : 153 8.
23. Uitto J, Helin P, Rasmussen O, Lorenzen I. Skin collagen in patients with scleroderma: biosynthesis and maturation in vitro, and the effect of D-penicillamine. Ann Clin Res 1970 2 : 228 34.
24. Lorenzen IB, Uitto J, Ohlenschlaeger K. D-penicillamine in progressive scleroderma. Scand J Rheumatol 1972 1 : 121 4.
25. Herbert CM, Lindberg KA, Jayson MI, Bailey AJ. Biosynthesis and maturation of skin collagen in scleroderma, and effect of D-penicillamine. Lancet 1974 i : 187 92.
26. Rodnan GP. Progressive systemic sclerosis and penicillamine. J Rheumatol 1981 7 (Suppl. 116 20.
27. Medsger TA Jr., Lucas M, Wildy KS, Baker C. D-penicillamine in systemic sclerosis? Yes. Scand J Rheumatol 2001 30 : 192 4.
28. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001 44 : 2828 35.
29. Brennan P, Silman A, Black C et al. Reliability of skin involvement measures in scleroderma. Br J Rheumatol 1992 31 : 457 60.
30. Miller SF, Finley RK, Waltman M, Lincks J. Burn size estimate reliability: a study. J Burn Care Rehabil 1991 12 : 546 59.
31. Medsger TA Jr., Silman AJ, Steen VD et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999 26 : 2159 67.
32. Medsger TA Jr., Bombardieri S, Czirjak L et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003 21 : S42 6.
33. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980 23 : 581 90.
34. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988 15 : 202 5.
35. Ortonne JP, Torzouli C, Dujardin P et al. Ketanserin in the treatment of systemic sclerosis: a double-blind controlled trial. Br J Dermatol 1989 120 : 261 6.